Skip to content

Lithium Americas LAC Issuance of warrants to purchase common stock

Issuance of warrants to purchase common stock at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%
ADMA Biologics logo
ADMA BiologicsADMA
$1.4M
Evommune
 logo
Evommune EVMN
$150
NovaGold Resources logo
NovaGold ResourcesNG
$9.9M
GigaCloud Technology logo
GigaCloud TechnologyGCT
$187K0.0%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$409.25K

Other financials

Income statement

See full
Net income$4.6M+140%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$758.5M+69.8%
Total debt$702.9M
Total equity$1.3B+115%
Total assets$3.1B+206%

Cash flow

See full
Operating cash flow-$18.3M+3.1%
CapEx$299.3M+154%
Free cash flow-$317.6M-132%

Valuation

See full
Market cap$1.38B+150%
Enterprise value$1.33B

Returns & leverage

See full
Return on equity-8.4%
Debt / equity0.5×
Current ratio7.4×-3.0×

Where this comes from

Reported directly by Lithium Americas in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.

The official record: Lithium Americas’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lithium Americas's issuance of warrants to purchase common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lithium Americas's issuance of warrants to purchase common stock?
Lithium Americas (LAC) reported issuance of warrants to purchase common stock of $88.59M in Q1 2026.